Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer

NCT04550104 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.

NCT NCT04550104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04550104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer
Lead sponsor
University of Leeds
Phase
Phase 1
Overall status
Recruiting
Start date
March 17, 2021
Completion date
March 31, 2028
Enrollment
200 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer